Abstract
Background
Only a small percentage of candidates for bariatric surgery ever undergo a procedure for weight loss. Devices duplicating key effects of bariatric surgeries with removable, fully trans-oral implants could extend their benefits to patients unwilling to undergo anatomy-altering abdominal surgeries.
Methods
Thirty-two obese subjects (mean BMI: 42.3) were enrolled in a prospective, multicenter, single-arm, feasibility trial of the first fully trans-oral endoscopic gastrointestinal bypass device. The device is a cuff attached to the distal esophagus by transmural anchors and connected to a 120-cm sleeve diverting undigested nutrients to the jejunum. Bodyweight, vital signs, adverse events, medications, HbA1c, fasting glucose, and lipids were collected at baseline and follow-up visits. Device status was endoscopically assessed every 6 months.
Results
The fully trans-oral procedure was successful in all subjects without intraoperative adverse events or postoperative infections. Twenty-eight of 32 subjects (88%) remained implanted with continuing follow-up beyond their 12-month visit. At 12 months, the 32 subjects had lost an average of 44.8% of excess body weight, 17.6% of total body weight, 20.8 kg, and 7.5 BMI points. Weight loss depended on capture of ingesta by the esophageal cuff, with 18 of 32 subjects without visible gaps around their cuffs at the 6 month endoscopy having significantly greater EWL (53.6 vs. 33.4% in the remaining subjects, p < 0.002). Mean HbA1c and fasting glucose declined by 1.1% points and 29 mg/dL in type 2 diabetic subjects, 80% of whom had remission of their diabetes at 12 months.
Conclusion
This study demonstrates the feasibility, safety, and efficacy of a fully trans-oral gastrointestinal bypass implant. This purely endoscopic device may provide a valuable addition to the armamentarium of treatment available for the management of morbid obesity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
O’Brien PE, Dixon JB, Laurie C, Skinner S, Proietto J, McNeil J, Strauss B, Marks S, Schachter L, Chapman L, Anderson M (2006) Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 144:625–633
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR, Investigators S (2014) Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 370:2002–2013
Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683–2693
American Society for Bariatric and Metabolic Surgery (2014) New procedure estimates for bariatric surgery: what the numbers reveal. ASMBS Connect, May 2014
Nguyen NT, Vu S, Kim E, Bodunova N, Phelan MJ (2015) Trends in utilization of bariatric surgery, 2009–2012. Surg Endosc 30:1–5
National Institute of Diabetes and Digestive and Kidney Diseases (1991) Gastrointestinal surgery for severe obesity. NIH Consens Statement 9:1–20
US Centers for Disease Control and Prevention (2014) Behavioral risk factor surveillance system 2004–2013. CDC, Atlanta
Sarwer DB, Ritter S, Wadden TA, Spitzer JC, Vetter ML, Moore RH (2013) Attitudes about the safety and efficacy of bariatric surgery among patients with type 2 diabetes and a body mass index of 30–40 kg/m2. Surg Obes Relat Dis 9:630–635
Stanford FC, Kyle TK, Claridy MD, Nadglowski JF, Apovian CM (2015) The influence of an individual’s weight perception on the acceptance of bariatric surgery. Obesity 23:277–281
Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, Schultz S, Talamini M, Horgan S (2011) Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 25:3028–3033
Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, Schultz S, Talamini MA, Jacobsen GR, Horgan S (2015) One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 29:3298–3303
Kolotkin RL, Crosby RD (2002) Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample. Qual Life Res 11:157–171
US Department of Health and Human Services (2009) Common terminology criteria for adverse events (CTCAE) version 4.0. US DHHS, Washington, DC
International Standards Organization (2011) ISO 14155:2011(EN) Clinical investigation of medical devices for human subjects—good clinical practice. ISO, Geneva
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Drs. Sandler, Rumbaut, Morales-Garza, Smith, and Horgan are consultants of ValenTx, Inc. Dr. Biertho received grant funding from ValenTx, Inc. during the conduct of this study. Dr. Torres-Barrera received consulting fee from the Instituto Technologico de Monterrey during the conduct of this study. Drs. Anvari, Marceau, and Hong have no conflicts of interest or financial ties to disclose.
Rights and permissions
About this article
Cite this article
Sandler, B.J., Biertho, L., Anvari, M. et al. Totally endoscopic implant to effect a gastric bypass: 12-month safety and efficacy outcomes. Surg Endosc 32, 4436–4442 (2018). https://doi.org/10.1007/s00464-018-6186-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-018-6186-0